Alumis FY2025 EPS Estimate Decreased by Cantor Fitzgerald

Alumis Inc. (NASDAQ:ALMS - Free Report) - Cantor Fitzgerald dropped their FY2025 earnings estimates for Alumis in a research note issued to investors on Thursday, March 20th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will post earnings of ($5.36) per share for the year, down from their prior estimate of ($4.13). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Alumis' current full-year earnings is ($8.51) per share.

Several other research analysts have also commented on ALMS. HC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of Alumis in a report on Wednesday. Oppenheimer began coverage on shares of Alumis in a research note on Thursday, January 30th. They issued an "outperform" rating and a $32.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $26.00.

Alumis Stock Down 4.5 %

Shares of ALMS traded down $0.22 during mid-day trading on Monday, reaching $4.70. The company had a trading volume of 755,477 shares, compared to its average volume of 276,772. The firm has a fifty day simple moving average of $5.49 and a 200-day simple moving average of $8.40. Alumis has a fifty-two week low of $3.18 and a fifty-two week high of $13.53.

Remove Ads

Institutional Investors Weigh In On Alumis

A number of hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets acquired a new stake in shares of Alumis in the 3rd quarter worth about $27,000. Wells Fargo & Company MN raised its position in shares of Alumis by 77.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,779 shares of the company's stock worth $69,000 after buying an additional 3,823 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Alumis by 4.3% in the 4th quarter. Northern Trust Corp now owns 111,326 shares of the company's stock worth $875,000 after acquiring an additional 4,587 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Alumis by 4.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 113,401 shares of the company's stock worth $891,000 after buying an additional 4,808 shares in the last quarter. Finally, Barclays PLC lifted its holdings in shares of Alumis by 33.9% in the fourth quarter. Barclays PLC now owns 24,581 shares of the company's stock valued at $193,000 after buying an additional 6,221 shares during the period.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.